arrow
M

Merete Lund Hetland

centre for head and orthopaedics
H指数:68
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression of sacroiliac joint structural lesions in axial spondyloarthritis: a longitudinal comparative study of MRI and radiography among European patients in routine clinical care

轴性脊柱关节炎患者骶髂关节结构病变的进展:欧洲常规临床护理中患者的MRI与放射影像纵向比较研究

2026-10-130
OAAI
Patients improve, patterns persist: longitudinal stability of RA joint involvement patterns

患者改善,模式持续:类风湿关节炎关节受累模式的纵向稳定性

2026-10-050
OAAI
The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis

通过钙卫蛋白测量的系统性炎症与类风湿关节炎中自身抗体负荷的关联

2026-10-030
OAAI
Drug concentrations and anti-drug antibodies in patients with arthritis treated with infliximab and adalimumab - comparison of three assays

类风湿关节炎患者使用英夫利昔单抗和阿达木单抗治疗时的药物浓度和抗药抗体水平——三种检测方法的比较

2026-09-040
OAAI
Cannabidiol for chronic pain in rheumatoid arthritis and ankylosing spondylitis: a randomized, placebo-controlled trial with exploratory tetrahydrocannabinol add-on

大麻二酚治疗类风湿关节炎和强直性脊柱炎慢性疼痛:一项随机、安慰剂对照试验,并探索性添加四氢大麻酚

2026-08-310
OA
Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis

定义并验证改良纽约标准放射学部分的高特异性MRI截断值在轴性脊柱关节炎患者中的应用

2026-07-170
OA
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial

Certolizumab pegol、abatacept、tocilizumab或早期类风湿关节炎的活性常规疗法:NORD-STAR试验的48周患者报告结局

2026-03-230
PRE
Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care

使用生物类似药英夫利昔单抗(GP1111)进行常规治疗的情况下,2132名患有炎症性关节炎的丹麦患者的安全结局。

2025-12-230
OA
Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis

定义巴思强直性脊柱炎疾病活动指数(BASDAI)截断值,以评估欧洲多国轴性脊柱关节炎患者队列中的疾病活动状态。

2025-12-020
OAAI
Sacroiliac joint involvement in psoriatic arthritis – MRI, radiographic and clinical findings in 581 European routine care patients

银屑病关节炎中骶髂关节的受累情况——581例欧洲常规护理患者的MRI、放射影像学和临床发现

2025-10-030
OA
Correction: Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort

更正:早期类风湿关节炎的疾病活动度和治疗反应:NORD-STAR队列的一项探索性代谢组学分析

2025-10-030
OA
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint

酰基肉碱富集作为类风湿关节炎成纤维样滑膜细胞代谢指纹的特征

2025-08-190
OAAI
Association of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid Arthritis

可溶性免疫检查点分子PD1和4-1BB与早期类风湿关节炎CTLA-4Ig治疗反应的关联

2025-07-070
OAAI
Cohort profile: Copenhagen Hospital Biobank-chronic inflammatory disease—inflammatory bowel disease (CHB-CID:IBD) genetic cohort

队列概要:哥本哈根医院生物库—慢性炎症性疾病—炎症性肠病(CHB-CID:IBD)遗传队列

2025-06-090
OAAI
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

欧洲各国在组织治疗银屑病关节炎和轴向脊柱关节炎患者方面的国家医疗体系存在差异。

2025-06-010
OAAI
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
2025-05-011
OAAI
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

识别甘氨酸与瓜氨酸基序对决定抗瓜氨酸蛋白抗体与HLA II类分子结合的影响:来自对6,900名斯堪的纳维亚类风湿关节炎患者自身抗体谱分析的研究启示

2025-04-300
OAAI
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
2025-02-280
OAAI
Chronic inflammation is associated with impaired cardiac structure and function in patients with inflammatory arthritis: the ARTCADIA Study
2024-10-280
PRE